Patents by Inventor Pablo Umaña

Pablo Umaña has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250101132
    Abstract: The present invention relates to the combination therapy of a bispecific antibody which binds human TYRP1 and CD3 and a second TYRP1-specific antibody.
    Type: Application
    Filed: May 20, 2024
    Publication date: March 27, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Valeria G. NICOLINI, Pablo UMAÑA
  • Publication number: 20250101135
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: June 10, 2024
    Publication date: March 27, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Regula, Pablo Umana
  • Patent number: 12258371
    Abstract: The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 25, 2025
    Assignee: Hoffman-La Roche Inc.
    Inventors: Laura Deak Codarri, Stefan Dengl, Jens Fischer, Thomas Hofer, Laurent Lariviere, Ekkehard Moessner, Stefan Seeber, Pablo Umana, Anne-Claire Zagdoun
  • Publication number: 20250092128
    Abstract: The present invention generally relates to improved Protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. Furthermore, the invention relates to novel Protease-cleavable peptide linkers and their used in such Protease-activatable antigen-binding molecules. In addition, the present invention relates to polynucleotides encoding such Protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the Protease-activated T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.
    Type: Application
    Filed: September 30, 2024
    Publication date: March 20, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Christian KLEIN, Pablo UMAÑA
  • Publication number: 20250073308
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 18, 2024
    Publication date: March 6, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umaña, Inja Waldhauer
  • Patent number: 12240911
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: March 4, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Viktor Levitski, Pablo Umana
  • Publication number: 20250066448
    Abstract: The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.
    Type: Application
    Filed: July 26, 2024
    Publication date: February 27, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Teemu Tapani JUNTTILA, Christian KLEIN, Pablo UMANA, Christina CLAUS
  • Publication number: 20250059298
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: July 26, 2024
    Publication date: February 20, 2025
    Inventors: Stephan GASSER, Thomas HOFER, Teemu Tapani JUNTTILA, Christian KLEIN, Christine KUETTEL, Jenny Tosca THOM, Pablo UMAÑA
  • Publication number: 20250043028
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 18, 2024
    Publication date: February 6, 2025
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Patent number: 12215155
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: February 4, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • Publication number: 20250034269
    Abstract: The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 18, 2024
    Publication date: January 30, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberta Bianchi, Felix Bormann, Michelle Victoria Brydon, Stefan Dengl, Harald Duerr, Guy Georges, Lydia Jasmin Hanisch, Monika Heidrich, Ralf Hosse, Leo Frederik Kunz, Stephane Leclair, Desirée Leisibach, Fanny Mende, Olaf Mundigl, Miroslav Nikolov, Pablo Umaña, Cornelia Wagner
  • Patent number: 12202870
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 21, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Publication number: 20240425561
    Abstract: Provided are mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, provided are polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. Also provided are methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 12, 2024
    Publication date: December 26, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alejandro CARPY GUTIERREZ CIRLOS, Laura CODARRI DEAK, Greta DURINI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Johann KOLL, Laura LAUENER, Ekkehard MOESSNER, Valeria NICOLINI, Cindy SCHULENBURG, Pablo UMAÑA
  • Publication number: 20240425616
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 9, 2024
    Publication date: December 26, 2024
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Publication number: 20240383987
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: April 17, 2024
    Publication date: November 21, 2024
    Inventors: Tina WEINZIERL, Lydia Jasmin HANISCH, Alexander BUJOTZEK, Alejandro CARPY GUTIERREZ CIRLOS, Stefan KLOSTERMANN, Christian KLEIN, Simon Patrick KEISER, Tanja FAUTI, Estelle MARRER-BERGER, Pablo UMAÑA
  • Patent number: 12145994
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: November 19, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Alexander Bujotzek, Harald Duerr, Guy Georges, Christian Klein, Stephane Leclair, Moritz Rapp, Eva Carina Sum, Christine Trumpfheller, Pablo Umaña
  • Publication number: 20240376171
    Abstract: The present invention generally relates to novel isolated polypeptides and immunoconjugates and their uses. The polypeptides and immunoconjugates comprise at least one protease recognitions sequence, which is a substrate for matriptase.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Samuele CALABRO, Peter BRUENKER, Linda FAHRNI, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Evelyn SAUER, Pablo UMAÑA, Inja WALDHAUER
  • Publication number: 20240376205
    Abstract: The invention provides fusion proteins that comprise a human IFN-?2, a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and to human IFN-?2, and methods of using the same.
    Type: Application
    Filed: May 7, 2024
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jack Anthony BATES, Davide BERTOLDO, Ulrich BRINKMANN, Harald DUERR, Moritz RAPP, Jasmin SYDOW-ANDERSEN, Pablo UMAÑA, Monika WOLF
  • Patent number: 12139553
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 12, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Peter Bruenker, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Publication number: 20240368309
    Abstract: The present invention relates to bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28 comprising new humanized EpCAM antibodies, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 1, 2023
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Jenny Tosca THOM, Pablo UMANA, Tina WEINZIERL